Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DEBORAH G NIXON

Allopathic & Osteopathic Physicians Dermatology

NPI
1073575684
CMS profile
963336
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$608.13

29 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $608.13 29

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $291.60 16
Lilly USA, LLC $141.81 3
GENZYME CORPORATION $45.77 3
Novartis Pharmaceuticals Corporation $41.92 2
LEO Pharma Inc. $24.98 1
Allergan, Inc. $22.78 1
E.R. Squibb & Sons, L.L.C. $14.56 1
PFIZER INC. $13.06 1
Almirall LLC $11.65 1

Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DEBORAH G NIXON

NPI 1073575684 · CMS profile ID 963336

Allopathic & Osteopathic Physicians / Dermatology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073575684?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DEBORAH G NIXON, NPI 1073575684, CMS profile ID 963336. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073575684?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DEBORAH G NIXON, NPI 1073575684, CMS profile ID 963336. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073575684?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DEBORAH G NIXON, NPI 1073575684, CMS profile ID 963336, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1073575684?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

29 matching records · $608.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 29 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–29 of 29.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $13.0612/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949608441 CMS
E.R. Squibb & Sons, L.L.C. $14.5611/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932864281 CMS
GENZYME CORPORATION $15.9811/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938808247 CMS
Lilly USA, LLC $8.8311/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918052727 CMS
ABBVIE INC. $13.9110/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263763 CMS
GENZYME CORPORATION $14.0710/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938808237 CMS
Almirall LLC $11.6510/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902853161 CMS
ABBVIE INC. $15.2410/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263761 CMS
ABBVIE INC. $13.0209/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263759 CMS
Lilly USA, LLC $111.4308/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917973619 CMS
ABBVIE INC. $97.4708/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263757 CMS
ABBVIE INC. $13.9408/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263755 CMS
ABBVIE INC. $11.6508/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263753 CMS
Lilly USA, LLC $21.5507/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918016389 CMS
Allergan, Inc. $22.7807/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889953487 CMS
ABBVIE INC. $12.6207/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263751 CMS
ABBVIE INC. $15.0406/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263749 CMS
ABBVIE INC. $20.0105/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263747 CMS
Novartis Pharmaceuticals Corporation $23.2204/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894030443 CMS
ABBVIE INC. $10.3404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263745 CMS
Novartis Pharmaceuticals Corporation $18.7003/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894030439 CMS
ABBVIE INC. $10.8103/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263743 CMS
GENZYME CORPORATION $15.7202/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938808143 CMS
ABBVIE INC. $20.1802/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263741 CMS
ABBVIE INC. $6.4702/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263739 CMS
ABBVIE INC. $17.5902/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263737 CMS
LEO Pharma Inc. $24.9802/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936261355 CMS
ABBVIE INC. $6.5901/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263735 CMS
ABBVIE INC. $6.7201/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891263733 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $590.27 37
PY2020 $227.01 10
PY2021 $416.17 22
PY2022 $608.13 29
PY2023 $275.09 10
PY2024 $304.19 15
PY2025 $1,096.15 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $296,458.78 66
PY2024 Principal investigator $247,116.67 29
PY2023 Principal investigator $166,737.83 35
PY2022 Recipient $123.00 1
PY2022 Principal investigator $34,841.75 6
PY2021 Principal investigator $52,302.21 8
PY2020 Recipient $2,108.59 2
PY2020 Principal investigator $97,200.02 2
PY2019 Recipient $39,789.75 2
PY2019 Principal investigator $7,564.30 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $6,841.52 12/31/2024 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130969215
Principal investigator 1 PFIZER INC. $5,045.95 12/25/2024 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130969744
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,357.50 12/18/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792270
Principal investigator 1 PFIZER INC. $8,732.64 12/05/2024 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130970086
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,369.75 11/13/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792268
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,819.56 10/17/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792266
Principal investigator 1 SANOFI US SERVICES INC. $17,250.00 10/02/2024 Non-covered Recipient Entity
Djl Clinical Research
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1128719331
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,511.44 09/24/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792264
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,616.25 08/22/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792262
Principal investigator 1 Amgen Inc. $11,351.00 07/26/2024 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309161
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,634.69 07/23/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792260
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,392.63 06/21/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792258
Principal investigator 1 PFIZER INC. $1,306.50 06/01/2024 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131068141
Principal investigator 1 Amgen Inc. $19,157.00 05/24/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF CHARLOTTE
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309143
Principal investigator 1 Eli Lilly and Company $14,609.39 05/24/2024 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1137358235
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,493.00 05/17/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792256
Principal investigator 1 PFIZER INC. $16,683.00 05/04/2024 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131079774
Principal investigator 1 Amgen Inc. $9,522.50 04/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF CHARLOTTE
IGNITE P3 AD Adult Monotherapy Study 1 No dispute reported 06/30/2026 1096310975
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,369.75 04/17/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792254
Principal investigator 1 Eli Lilly and Company $4,497.00 04/12/2024 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1137358409
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,146.13 03/18/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792252
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,757.94 02/16/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792250
Principal investigator 1 PFIZER INC. $1,279.80 02/15/2024 Non-covered Recipient Entity
Dermatology Specialists of Charlotte
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130916799
Principal investigator 1 PFIZER INC. $2,257.20 02/15/2024 Non-covered Recipient Entity
Dermatology Specialists of Charlotte
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130918440
Principal investigator 1 Amgen Inc. $10,655.81 01/25/2024 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309163
Principal investigator 1 Amgen Inc. $96.08 01/25/2024 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
IGNITE P3 AD Adult Monotherapy Study 1 No dispute reported 06/30/2026 1096310979
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,860.88 01/25/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792248
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $16,209.76 01/23/2024 Non-covered Recipient Entity
DJL Clinical Research, PLLC
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151792274
Principal investigator 1 Eli Lilly and Company $1,292.00 01/09/2024 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1137358487